Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)

被引：8

作者：

Chau, Ian

Penel, Nicolas

Arkenau, Hendrik-Tobias

Santana-Davila, Rafael

Calvo, Emiliano

Soriano, Andres O.

Mi, Gu

Jin, Jin

Ferry, David

Herbst, Roy S.

Fuchs, Charles S.

机构：

[1] Royal Marsden NHS Fdn Trust, London, England

[2] Ctr Oscar Lambret, Lille, France

[3] Sarah Cannon Res Inst, London, England

[4] Univ Washington, Seattle, WA USA

[5] START Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain

[6] Florida Canc Specialist, Miami, FL USA

[7] Eli Lilly & Co, Indianapolis, IN USA

[8] Eli Lilly & Co, Bridgewater, NJ USA

[9] Yale Univ, Yale Sch Med, New Haven, CT USA

[10] Yale New Haven Hlth, Smilow Canc Hosp, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期

关键词：

D O I：

10.1200/JCO.2018.36.4_suppl.101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

101

引用

页数：1

共 50 条

[21] Phase II study of cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results (FOLCETUX study)
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Rojas Llimpe, F. L.
Ceccarelli, C.
Mutri, V
Giaquinta, S.
Piana, E.
Martoni, A. A.
[J]. ANNALS OF ONCOLOGY, 2006, 17 : XI54 - XI55
[22] Cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results of folcetux phase II study
Di Fabio, Francesca
Pinto, Carmine
Siena, Salvatore
Cascinu, Stefano
Ceccarelli, Claudio
Llimpe, Fabiola Lorena Rojas
Mutri, Vita
Giaquinta, Stefania
Piana, Edera
Martoni, Andrea Angelo
[J]. ANNALS OF ONCOLOGY, 2006, 17 : 309 - 310
[23] Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Wyrwicz, L.
Oh, D.
Weber, P.
Bai, Y.
Ryu, M.
Lee, J.
Rivera, F.
Alves, G. Vasconcelos
Garrido, M.
Shiu, K.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Rha, S.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S181 - S181
[24] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
Menglong Zhou
Wang Yang
Yan Xuan
Wei Zou
Yaqi Wang
Zhiyuan Zhang
Jing Zhang
Miao Mo
Changming Zhou
Yuan Liu
Wenming Zhang
Zhaozhen Zhang
Yiping He
Weiwei Weng
Cong Tan
Lei Wang
Dan Huang
Weiqi Sheng
Huanhuan Li
Hui Zhu
Yan Wang
Lijun Shen
Hui Zhang
Juefeng Wan
Guichao Li
Hua Huang
Yanong Wang
Zhen Zhang
Xiaowen Liu
Fan Xia
[J]. BMC Cancer, 22
[25] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
Zhou, Menglong
Yang, Wang
Xuan, Yan
Zou, Wei
Wang, Yaqi
Zhang, Zhiyuan
Zhang, Jing
Mo, Miao
Zhou, Changming
Liu, Yuan
Zhang, Wenming
Zhang, Zhaozhen
He, Yiping
Weng, Weiwei
Tan, Cong
Wang, Lei
Huang, Dan
Sheng, Weiqi
Li, Huanhuan
Zhu, Hui
Wang, Yan
Shen, Lijun
Zhang, Hui
Wan, Juefeng
Li, Guichao
Huang, Hua
Wang, Yanong
Zhang, Zhen
Liu, Xiaowen
Xia, Fan
[J]. BMC CANCER, 2022, 22 (01)
[26] Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
Herbst, R. S.
Martin-Liberal, J.
Calvo, E.
Isambert, N.
Bendell, J. C.
Cassier, P.
Perez-Gracia, J. L.
Yang, J.
Rege, J.
Mi, G.
Ferry, D.
Paz-Ares, L.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[27] Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Xu, J.
Jiang, H.
Pan, Y.
Gu, K.
Cang, S.
Han, L.
Shu, Y.
Li, J.
Zhao, J.
Pan, H.
Luo, S.
Qin, Y.
Guo, Q.
Bai, Y.
Ling, Y.
Guo, Y.
Li, Z.
Liu, Y.
Wang, Y.
Zhou, H.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1331 - S1331
[28] Phase III KEYNOTE-585 study of chemotherapy (Chemo) plus pembrolizumab (Pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Y-J.
Van Cutsem, E.
Fuchs, C. S.
Ohtsu, A.
Tabernero, J.
Ilson, D. H.
Hyung, W. J.
Strong, V. E.
Goetze, T. O.
Yoshikawa, T.
Tang, L. H.
Hwang, P. M. T.
Adelberg, D.
Shitara, K.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 268 - 268
[29] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Qin, S.
Tabernero, J.
van Cutsem, E.
Fuchs, C. S.
Janjigian, Y. Y.
Bhagia, P.
Li, K.
Adelberg, D.
Bang, Y-J.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
[30] FOLFiRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab for Patients with Advanced or Metastatic Adenocarcinoma of The Stomach or Gastroesophageal Junction As Second-Line Therapy - Interim Safety and Efficacy Results from The Phase II Ramiris Study (AIO-STO-0415) of the German Gastric Group at AIO
Lorenzen, Sylvie
Thuss-Patience, Peter
Pauligk, Claudia
Goekkurt, Eray
Ettrich, Thomas J.
Lordick, Florian
Stahl, Michael
Reichardt, Peter
Soekler, Martin
Pink, Daniel
Probst, Stephan
Alguel, Nana
Hinke, Axel
Goetze, Thorsten
Al-Batran, Salah-Eddin
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 58 - 58

← 1 2 3 4 5 →